Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
Identifieur interne : 001487 ( PubMed/Checkpoint ); précédent : 001486; suivant : 001488Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
Auteurs : Yun Fu [États-Unis] ; Debra Chung ; Minh-An Cao ; Sophia Apple ; Helena ChangSource :
- Annals of surgical oncology [ 1534-4681 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Aisselle (), Analyse de survie, Biopsie de noeud lymphatique sentinelle, Femelle, Humains, Indoles, Invasion tumorale, Lymphadénectomie (), Marqueurs biologiques tumoraux (sang), Mastectomie, Modèles de hasards proportionnels, Phénylpropionates, Radiothérapie adjuvante, Récepteur ErbB-2 (sang), Résultat thérapeutique, Sensibilité et spécificité, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du sein (), Tumeurs du sein (diagnostic), Tumeurs du sein (mortalité), Tumeurs du sein (radiothérapie), Tumeurs du sein (sang), Valeur prédictive des tests, Études de suivi, Études rétrospectives.
- MESH :
- diagnostic : Tumeurs du sein.
- mortalité : Tumeurs du sein.
- radiothérapie : Tumeurs du sein.
- sang : Marqueurs biologiques tumoraux, Récepteur ErbB-2, Tumeurs du sein.
- Adulte, Adulte d'âge moyen, Aisselle, Analyse de survie, Biopsie de noeud lymphatique sentinelle, Femelle, Humains, Indoles, Invasion tumorale, Lymphadénectomie, Mastectomie, Modèles de hasards proportionnels, Phénylpropionates, Radiothérapie adjuvante, Résultat thérapeutique, Sensibilité et spécificité, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du sein, Valeur prédictive des tests, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Axilla (surgery), Biomarkers, Tumor (blood), Breast Neoplasms (blood), Breast Neoplasms (diagnosis), Breast Neoplasms (mortality), Breast Neoplasms (radiotherapy), Breast Neoplasms (surgery), Female, Follow-Up Studies, Humans, Indoles, Lymph Node Excision (methods), Mastectomy, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Phenylpropionates, Predictive Value of Tests, Proportional Hazards Models, Radiotherapy, Adjuvant, Receptor, ErbB-2 (blood), Retrospective Studies, Sensitivity and Specificity, Sentinel Lymph Node Biopsy, Survival Analysis, Treatment Outcome.
- MESH :
- chemical , blood : Biomarkers, Tumor, Receptor, ErbB-2.
- blood : Breast Neoplasms.
- diagnosis : Breast Neoplasms.
- methods : Lymph Node Excision.
- mortality : Breast Neoplasms.
- radiotherapy : Breast Neoplasms.
- surgery : Axilla, Breast Neoplasms.
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Indoles, Mastectomy, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Phenylpropionates, Predictive Value of Tests, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Sensitivity and Specificity, Sentinel Lymph Node Biopsy, Survival Analysis, Treatment Outcome.
Abstract
The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial reported that axillary lymph node dissection (ALND) did not change the recurrence and overall survival (OS) rates in patients with lumpectomy and one to two positive nodes detected by sentinel lymph node biopsy (SLNB). The aim of this study was to determine whether patients with mastectomy and pathological N1 disease found by SLNB could forego ALND.
DOI: 10.1245/s10434-014-3814-3
PubMed: 25081336
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25081336Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?</title><author><name sortKey="Fu, Yun" sort="Fu, Yun" uniqKey="Fu Y" first="Yun" last="Fu">Yun Fu</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Chung, Debra" sort="Chung, Debra" uniqKey="Chung D" first="Debra" last="Chung">Debra Chung</name></author><author><name sortKey="Cao, Minh An" sort="Cao, Minh An" uniqKey="Cao M" first="Minh-An" last="Cao">Minh-An Cao</name></author><author><name sortKey="Apple, Sophia" sort="Apple, Sophia" uniqKey="Apple S" first="Sophia" last="Apple">Sophia Apple</name></author><author><name sortKey="Chang, Helena" sort="Chang, Helena" uniqKey="Chang H" first="Helena" last="Chang">Helena Chang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25081336</idno><idno type="pmid">25081336</idno><idno type="doi">10.1245/s10434-014-3814-3</idno><idno type="wicri:Area/PubMed/Corpus">001418</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001418</idno><idno type="wicri:Area/PubMed/Curation">001418</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001418</idno><idno type="wicri:Area/PubMed/Checkpoint">001418</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001418</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?</title><author><name sortKey="Fu, Yun" sort="Fu, Yun" uniqKey="Fu Y" first="Yun" last="Fu">Yun Fu</name><affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Chung, Debra" sort="Chung, Debra" uniqKey="Chung D" first="Debra" last="Chung">Debra Chung</name></author><author><name sortKey="Cao, Minh An" sort="Cao, Minh An" uniqKey="Cao M" first="Minh-An" last="Cao">Minh-An Cao</name></author><author><name sortKey="Apple, Sophia" sort="Apple, Sophia" uniqKey="Apple S" first="Sophia" last="Apple">Sophia Apple</name></author><author><name sortKey="Chang, Helena" sort="Chang, Helena" uniqKey="Chang H" first="Helena" last="Chang">Helena Chang</name></author></analytic><series><title level="j">Annals of surgical oncology</title><idno type="eISSN">1534-4681</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Axilla (surgery)</term><term>Biomarkers, Tumor (blood)</term><term>Breast Neoplasms (blood)</term><term>Breast Neoplasms (diagnosis)</term><term>Breast Neoplasms (mortality)</term><term>Breast Neoplasms (radiotherapy)</term><term>Breast Neoplasms (surgery)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Indoles</term><term>Lymph Node Excision (methods)</term><term>Mastectomy</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Phenylpropionates</term><term>Predictive Value of Tests</term><term>Proportional Hazards Models</term><term>Radiotherapy, Adjuvant</term><term>Receptor, ErbB-2 (blood)</term><term>Retrospective Studies</term><term>Sensitivity and Specificity</term><term>Sentinel Lymph Node Biopsy</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Aisselle ()</term><term>Analyse de survie</term><term>Biopsie de noeud lymphatique sentinelle</term><term>Femelle</term><term>Humains</term><term>Indoles</term><term>Invasion tumorale</term><term>Lymphadénectomie ()</term><term>Marqueurs biologiques tumoraux (sang)</term><term>Mastectomie</term><term>Modèles de hasards proportionnels</term><term>Phénylpropionates</term><term>Radiothérapie adjuvante</term><term>Récepteur ErbB-2 (sang)</term><term>Résultat thérapeutique</term><term>Sensibilité et spécificité</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (diagnostic)</term><term>Tumeurs du sein (mortalité)</term><term>Tumeurs du sein (radiothérapie)</term><term>Tumeurs du sein (sang)</term><term>Valeur prédictive des tests</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers, Tumor</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Lymph Node Excision</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Récepteur ErbB-2</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Axilla</term><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Indoles</term><term>Mastectomy</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Phenylpropionates</term><term>Predictive Value of Tests</term><term>Proportional Hazards Models</term><term>Radiotherapy, Adjuvant</term><term>Retrospective Studies</term><term>Sensitivity and Specificity</term><term>Sentinel Lymph Node Biopsy</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Aisselle</term><term>Analyse de survie</term><term>Biopsie de noeud lymphatique sentinelle</term><term>Femelle</term><term>Humains</term><term>Indoles</term><term>Invasion tumorale</term><term>Lymphadénectomie</term><term>Mastectomie</term><term>Modèles de hasards proportionnels</term><term>Phénylpropionates</term><term>Radiothérapie adjuvante</term><term>Résultat thérapeutique</term><term>Sensibilité et spécificité</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du sein</term><term>Valeur prédictive des tests</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial reported that axillary lymph node dissection (ALND) did not change the recurrence and overall survival (OS) rates in patients with lumpectomy and one to two positive nodes detected by sentinel lymph node biopsy (SLNB). The aim of this study was to determine whether patients with mastectomy and pathological N1 disease found by SLNB could forego ALND.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25081336</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>04</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-4681</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>13</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of surgical oncology</Title><ISOAbbreviation>Ann. Surg. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?</ArticleTitle><Pagination><MedlinePgn>4109-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-014-3814-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial reported that axillary lymph node dissection (ALND) did not change the recurrence and overall survival (OS) rates in patients with lumpectomy and one to two positive nodes detected by sentinel lymph node biopsy (SLNB). The aim of this study was to determine whether patients with mastectomy and pathological N1 disease found by SLNB could forego ALND.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This is a retrospective study of 214 patients diagnosed with primary invasive breast cancer who were treated by mastectomy and lymph node staging surgery (SLNB or ALND) at the Revlon/UCLA Breast Center between January 2002 and December 2010. Patients with pathological N1 disease were separated by their first nodal surgery into SLNB (subgroups: observation, radiation, and additional ALND with or without radiation) and ALND groups (subgroups: ALND with or without radiation).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After a median follow-up of 43.6 months, the OS and systemic relapse-free survival (RFS) rate of the radiation group and additional ALND group were significantly better than the observation group (p = 0.031 and 0.046, respectively). Human epidermal growth factor receptor 2 (HER2) expression was found to predict OS and patients' age, histological grade and HER2 expression predicted systemic recurrence. Compared with the SLNB group, pain (p = 0.021) and lymphedema (p = 0.043) occurred more frequently in the ALND group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Radiation was as effective as ALND in patients with mastectomy and N1 disease for OS and RFS rates, yet radiation after SLNB had fewer side effects than ALND. SLNB followed by radiation could replace ALND in patients with mastectomy and pathological N1 breast cancer identified by SLNB.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Minh-An</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Apple</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg Oncol</MedlineTA><NlmUniqueID>9420840</NlmUniqueID><ISSNLinking>1068-9265</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561063">CO 068</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010666">Phenylpropionates</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="Y">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010666" MajorTopicYN="N">Phenylpropionates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021701" MajorTopicYN="Y">Sentinel Lymph Node Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25081336</ArticleId><ArticleId IdType="doi">10.1245/s10434-014-3814-3</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><noCountry><name sortKey="Apple, Sophia" sort="Apple, Sophia" uniqKey="Apple S" first="Sophia" last="Apple">Sophia Apple</name><name sortKey="Cao, Minh An" sort="Cao, Minh An" uniqKey="Cao M" first="Minh-An" last="Cao">Minh-An Cao</name><name sortKey="Chang, Helena" sort="Chang, Helena" uniqKey="Chang H" first="Helena" last="Chang">Helena Chang</name><name sortKey="Chung, Debra" sort="Chung, Debra" uniqKey="Chung D" first="Debra" last="Chung">Debra Chung</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Fu, Yun" sort="Fu, Yun" uniqKey="Fu Y" first="Yun" last="Fu">Yun Fu</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001487 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001487 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25081336
|texte= Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25081336" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |